We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
5 Big Winners as Dollar Strengthens on Fed Rate Hike
Read MoreHide Full Article
U.S. stocks took a beating on Sep 26, with the S&P 500 and the Dow sliding into a bear market. The broader S&P 500 has now tanked more than 20% from its Jan 3 record high. Similarly, the 30-stock Dow is down nearly 20.4% from its Jan 4 record.
The last time the blue-chip index slipped into the bear market was in early 2020 when the outburst of the coronavirus pandemic sparked a downturn in economic growth.
Sell-off on Wall Street has been broad-based, with multinational companies leading the pack. This is because a stronger U.S. dollar, at present, is now widely expected to impede their earnings growth. And why not? These companies derive a bulk of their earnings from overseas, which will now get exposed to foreign exchange risks in the United States and various other countries they are functioning in. Hence, a strengthening dollar will dent foreign sales of such multinational companies.
The U.S. dollar, by the way, soared to a new 20-year high against its major peers, with the British pound touching a fresh record low against the greenback on Sep 26. The euro, too, touched its lowest level versus the dollar since 2002.
In fact, a hawkish Fed has helped the spike in the dollar index. The central bank has now pledged to continue its aggressive tightening measures to tame a stubborn increase in inflation. The Fed has already increased its federal funds rate to its highest level since early 2008.
Nonetheless, such a continuous rise in interest rates eventually increases the value of a country’s currency. After all, higher interest rates draw foreign investments, thereby increasing the demand for the home currency, which explains why the dollar is strengthening amongst Fed rate hikes.
But purely from an investment perspective, even though a stronger dollar doesn’t bode well for multinational companies, it certainly acts as a boon for domestic players. This is because these companies generate the lion’s share of their revenues from within the country, which insulates them from the impact of a stronger dollar.
Consolidated Water designs, constructs, manages and operates water production and water treatment plants primarily in the United States. Consolidated Water has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up almost 9% over the past 60 days. The company’s expected earnings growth rate for the current year is 217.4%.
Ashford Hospitality Trust is a real estate investment trust. Ashford Hospitality Trust has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 19.4% over the past 60 days. The company’s expected earnings growth rate for the current year is 300%.
BankFinancial Corporation operates as the bank holding company for BankFinancial, National Association that provides various commercial, family, and personal banking products and services. BankFinancial has a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings has moved up 15.2% over the past 60 days. The company’s expected earnings growth rate for the current year is 71.7%.
LogicBio Therapeutics is a genetic medicine company. LogicBio Therapeutics has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 18.2% over the past 60 days. The company’s expected earnings growth rate for the current year is 41.9%.
ProPhase Labs engages in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products in the United States. ProPhase Labs has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 296.6% over the past 60 days. The company’s expected earnings growth rate for the current year is 475%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
5 Big Winners as Dollar Strengthens on Fed Rate Hike
U.S. stocks took a beating on Sep 26, with the S&P 500 and the Dow sliding into a bear market. The broader S&P 500 has now tanked more than 20% from its Jan 3 record high. Similarly, the 30-stock Dow is down nearly 20.4% from its Jan 4 record.
The last time the blue-chip index slipped into the bear market was in early 2020 when the outburst of the coronavirus pandemic sparked a downturn in economic growth.
Sell-off on Wall Street has been broad-based, with multinational companies leading the pack. This is because a stronger U.S. dollar, at present, is now widely expected to impede their earnings growth. And why not? These companies derive a bulk of their earnings from overseas, which will now get exposed to foreign exchange risks in the United States and various other countries they are functioning in. Hence, a strengthening dollar will dent foreign sales of such multinational companies.
The U.S. dollar, by the way, soared to a new 20-year high against its major peers, with the British pound touching a fresh record low against the greenback on Sep 26. The euro, too, touched its lowest level versus the dollar since 2002.
In fact, a hawkish Fed has helped the spike in the dollar index. The central bank has now pledged to continue its aggressive tightening measures to tame a stubborn increase in inflation. The Fed has already increased its federal funds rate to its highest level since early 2008.
Nonetheless, such a continuous rise in interest rates eventually increases the value of a country’s currency. After all, higher interest rates draw foreign investments, thereby increasing the demand for the home currency, which explains why the dollar is strengthening amongst Fed rate hikes.
But purely from an investment perspective, even though a stronger dollar doesn’t bode well for multinational companies, it certainly acts as a boon for domestic players. This is because these companies generate the lion’s share of their revenues from within the country, which insulates them from the impact of a stronger dollar.
Therefore, it is judicious to invest in stocks like Consolidated Water Co. Ltd. (CWCO - Free Report) , Ashford Hospitality Trust, Inc. (AHT - Free Report) , BankFinancial Corporation (BFIN - Free Report) , LogicBio Therapeutics, Inc. (LOGC - Free Report) and ProPhase Labs, Inc. (PRPH - Free Report) that have high domestic exposure in terms of revenue generation. They also boast a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Consolidated Water designs, constructs, manages and operates water production and water treatment plants primarily in the United States. Consolidated Water has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up almost 9% over the past 60 days. The company’s expected earnings growth rate for the current year is 217.4%.
Ashford Hospitality Trust is a real estate investment trust. Ashford Hospitality Trust has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 19.4% over the past 60 days. The company’s expected earnings growth rate for the current year is 300%.
BankFinancial Corporation operates as the bank holding company for BankFinancial, National Association that provides various commercial, family, and personal banking products and services. BankFinancial has a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings has moved up 15.2% over the past 60 days. The company’s expected earnings growth rate for the current year is 71.7%.
LogicBio Therapeutics is a genetic medicine company. LogicBio Therapeutics has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 18.2% over the past 60 days. The company’s expected earnings growth rate for the current year is 41.9%.
ProPhase Labs engages in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products in the United States. ProPhase Labs has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 296.6% over the past 60 days. The company’s expected earnings growth rate for the current year is 475%.